DLL4 Restores Damaged Liver by Enhancing hBMSC Differentiation into Cholangiocytes

Scientists aimed to determine whether human bone marrow mesenchymal stem cells can differentiate into biliary epithelial cells in vitro and in vivo and to clarify the role of delta-like ligand 4 (DLL4) in restoring damaged liver by enhancing cholangiocyte differentiation.
[Stem Cell Research]
Abstract

Continue reading “DLL4 Restores Damaged Liver by Enhancing hBMSC Differentiation into Cholangiocytes”

Bookmark

No account yet? Register

0
Share

Lung Delivery of MSCs Expressing Anti-Cancer Protein TRAIL Visualized with 89Zr-Oxine PET-CT

Investigators demonstrated 89Zr-oxine labeling and PET-CT imaging as a potential clinical solution for non-invasively tracking MSCTRAIL biodistribution
[Stem Cell Research & Therapy]
Full Article

Continue reading “Lung Delivery of MSCs Expressing Anti-Cancer Protein TRAIL Visualized with 89Zr-Oxine PET-CT”

Bookmark

No account yet? Register

0
Share

AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials

AVROBIO, Inc. announced that the first patient has been dosed in the company’s GuardOne clinical trial, a Phase I/II investigational study evaluating AVR-RD-02 for Gaucher disease type 1.
[AVROBIO, Inc.]
Press Release

Continue reading “AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials”

Bookmark

No account yet? Register

0
Share

Celixir Provides Update on Ongoing Clinical Program with Lead Therapeutic Candidate CLXR-001

Celixir announced an update to its ongoing clinical programme with lead therapeutic candidate CLXR-001.
[Celixir (GlobeNewswire, Inc.)]
Press Release

Continue reading “Celixir Provides Update on Ongoing Clinical Program with Lead Therapeutic Candidate CLXR-001”

Bookmark

No account yet? Register

0
Share

Adverum Biotechnologies Announces Completion of Patient Dosing in Cohort 4 of the OPTIC Phase I Trial of ADVM-022 Single Injection Gene Therapy for Wet AMD

Adverum Biotechnologies, Inc. announced the completion of patient dosing in Cohort 4 of OPTIC, a Phase I clinical trial, assessing a single intravitreal injection of ADVM-022 in patients with wet age-related macular degeneration.
[Adverum Biotechnologies, Inc.]
Press Release

Continue reading “Adverum Biotechnologies Announces Completion of Patient Dosing in Cohort 4 of the OPTIC Phase I Trial of ADVM-022 Single Injection Gene Therapy for Wet AMD”

Bookmark

No account yet? Register

0
Share

IgG-Cleaving Endopeptidase Enables In Vivo Gene Therapy in the Presence of Anti-AAV Neutralizing Antibodies

Investigators studied if imlifidase could eliminate anti-adeno-associated virus antibodies in the context of gene therapy.
[Nature Medicine]
Abstract

Continue reading “IgG-Cleaving Endopeptidase Enables In Vivo Gene Therapy in the Presence of Anti-AAV Neutralizing Antibodies”

Bookmark

No account yet? Register

0
Share

‘Disturbing and Cruel.’ Universities Blast New Visa Rule for International Students

A new US immigration policy, which threatens to revoke visas for certain international students if they are not taking in-person classes, is stirring panic and confusion and causing some universities to push back with lawsuits.
[Science]
Editorial

Continue reading “‘Disturbing and Cruel.’ Universities Blast New Visa Rule for International Students”

Bookmark

No account yet? Register

0
Share

US Bars International Students from Online-Only Learning in Fall

Since higher education institutions ended in-person classes in March due to the COVID-19 pandemic, there has been uncertainty over what classes will look like in the fall. Universities will soon have to come up with an answer.
[The Scientist]
Editorial

Continue reading “US Bars International Students from Online-Only Learning in Fall”

Bookmark

No account yet? Register

0
Share

An Optimist Takes the Helm at the National Science Foundation

The new director of the National Science Foundation (NSF), Sethuraman “Panch” Panchanathan, is familiar with the dark clouds over the agency. His boss, President Donald Trump, keeps proposing big cuts to NSF’s budget. Two recent executive orders on immigration make it harder for foreign scientists—who make up a sizeable share of the U.S. research enterprise—to enter the country.
[Science]
Press Release

Continue reading “An Optimist Takes the Helm at the National Science Foundation”

Bookmark

No account yet? Register

1+
Share

Defining an Optimal Dual-Targeted CAR T-Cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma

Scientists demonstrated that simultaneous targeting of an additional antigen—here, G protein-coupled receptor class-C group-5 member-D (GPRC5D)—can prevent B-cell maturation antigen escape–mediated relapse in a model of multiple myeloma. To identify an optimal approach, they compared subtherapeutic doses of different forms of dual-targeted cellular therapy.
[Blood Cancer Discovery]
Abstract

Continue reading “Defining an Optimal Dual-Targeted CAR T-Cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma”

Bookmark

No account yet? Register

1+
Share

Cabaletta Bio and Artisan Bio Announce Gene Editing Research and Collaboration Agreement to Develop Next-Generation CAAR T Cell Therapies

Cabaletta Bio, Inc. announced they have signed a research and collaboration agreement to accelerate development of next-generation CAAR T cell therapies for patients with B cell-mediated autoimmune diseases.
[Calbetta Bio, Inc.]
Press Release

Continue reading “Cabaletta Bio and Artisan Bio Announce Gene Editing Research and Collaboration Agreement to Develop Next-Generation CAAR T Cell Therapies”

Bookmark

No account yet? Register

0
Share
Share